Construction and Validation of a 15-Top-prognostic-gene-based Signature to Indicate the Dichotomized Clinical Outcome and Response to Targeted Therapy for Bladder Cancer Patients

Hongbing Gu1,2 and Chaozhao Liang1*

1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, Anhui Medical University and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China, 2Department of Urology, East District of First Affiliated Hospital of Anhui Medical University, Feidong People’s Hospital, Hefei, China

The clinical outcome of heterogeneous bladder cancer (BCa) is impacted by varying molecular characteristics and clinical features, and new molecular classification is necessary to recognize patients with dichotomized prognosis. We enrolled a total of 568 BCa patients from the TCGA-BLCA and GSE13507 cohorts. A total of 107 candidate genes, which were mostly involved in the extracellular matrix-associated pathway, were first selected through the consensus value of the area under the receiver operating characteristic curve (AUC). Furthermore, absolute shrinkage and selection operation regression analysis was implemented to reveal the 15 genes and establish the prognostic signature. The newly defined prognostic signature could precisely separate BCa patients into subgroups with favorable and poor prognosis in the training TCGA-BLCA cohort (p < 0.001, HR = 2.41, and 95% CI: 1.76–3.29), as well as the testing GSE13507 cohort (p < 0.001, HR = 7.32, and 95% CI: 1.76–3.29) and external validation E-MTAB-4321 cohort (p < 0.001, HR = 10.56, 95% CI: 3.208–34.731). Multivariate Cox analysis involving the signature and clinical features indicated that the signature is an independent factor for the prediction of BCa prognosis. We also explored potential targeted therapy for BCa patients with high- or low-risk scores and found that patients with high risk were more suitable for chemotherapy with gemcitabine, doxorubicin, cisplatin, paclitaxel, and vinblastine (all p < 0.05), but anti-PD-L1 therapy was useless. We knocked down HEYL with siRNAs in T24 and 5637 cells, and observed the decreased protein level of HEYL, and inhibited cell viability and cell invasion. In summary, we proposed and validated a 15-top-prognostic gene-based signature to indicate the dichotomized prognosis and response to targeted therapy.

Keywords: bladder cancer, target therapy, signature, prognosis, PDL1

Abbreviations: BCa, Bladder cancer; DEG, Differentially expressed gene; GEO, Gene Expression Omnibus; KM, Kaplan–Meier; ROC, Receiver operating characteristic; TCGA, The Cancer Genome Atlas.
INTRODUCTION

Bladder cancer (BCa), a common disease in the world with an estimated 430,000 new cases diagnosed in 2012, is the ninth most frequent tumor globally. Men have a higher incidence than women, accounting for 75% of patients. European male frequency tumor globally. Men have a higher incidence than estimated 430,000 new cases diagnosed in 2012, is the ninth most bladder cancer (BCa), a common disease in the world with an national Central Cancer Registry in China, the incidence of morbidity and mortality are rising. According to the 2015 BCa ranked sixth in male cancers, with 7.68/10^5 new cases diagnosed in 2011 (Pang et al., 2016). A total of 3.56/10^5 persons died of BCa in 2014 (Chen et al., 2018). Among the risk factors, smoking occupies the most important position, and approximately two-thirds of men and one-third of women with BCa are related to smoking (Farling, 2017). There are two types of BCa, muscle invasive BCa (MIBC) and non-muscle invasive BCa (NMIBC). NMIBC is also known as early-stage bladder cancer, and MIBC is an advanced stage with a high recurrence rate (Hautmann et al., 2006; Chamie et al., 2013).

As a heterogeneous disease, the clinical outcome of BCa is impacted by various characteristics in different patients, such as gene mutations, neoantigens, gene copy number alterations, and infiltration of immunocytes. Low-grade tumors have a low progression rate and a low short-term recurrence rate and can be removed easily by transurethral resection (TUR) or intravesical therapy with Bacillus Calmette-Guérin (BCG). However, 15.0%–20.0% of NMIBCs ultimately develop into invasive MIBCs (Hedegaard et al., 2016). At the other end of the spectrum, with a high short-term recurrence rate and a high malignant potential leading to tumor progression, high-grade tumors always have a poor prognosis (Kirkali et al., 2005). Therefore, it is important to establish an efficient and concise novel method to discriminate high-risk and low-risk BCa patients. Many teams have attempted to establish a novel classification of BCa at the molecular level. Mo et al. generated an 18-gene signature model to divide MIBC and NMIBC into two subgroups: basal and differentiated. The basal subgroup expressed a low signature gene level, and the differentiated subgroups expressed a high signature gene level. Further study showed a significant difference in overall survival time between the basal and differentiated subgroups. Compared with the differentiated subgroup, the basal subgroup had a worse overall survival outcome (Mo et al., 2018). Sjödahl et al. defined five major urothelial cancer subtypes using 308 cases, and 11 signature genes were identified. They broke the limitation of pathological staging and grading, adding more valuable information for pathological classification (Sjödahl et al., 2012). Kim et al. generated a progression-related gene classifier to predict the disease outcome of NMIBC patients (Kim W. J et al., 2010). Although many prognostic signatures and molecular subtypes have been found, they are still not mature enough to guide clinical therapy such as HER2 for breast cancer (Tsang and Tse, 2020).

Molecular classification is a novel, objectively assessed, individual, and functions as a complement to the classification system. Some genetic events, such as genetic or epigenetic changes that can cause aberrant gene expression, occur in the early stage of BCa (Kim and Quan, 2005; Kim and Bae, 2008). Thus, classification based on gene expression profiling represents a potentially useful way to discriminate different prognosis. In our novel molecular classification module, a total of 1,155 genes from TCGA and GSE13507 cohorts were enrolled and finally generated a 17-gene signature classifier.

MATERIALS AND METHODS

Data Collection

All expression profiles were derived from The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) and the Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/gds), and corresponding clinical information was obtained from the TCGA Bladder-cancer Clinical Data Resource dataset and GEO clinical data resource. After matching the available gene expression data and clinical features, a total of 403 patients from the TCGA-BLCA cohort and 165 patients from the GSE13507 cohort were recorded for the utilization of the current study.

Identification of Candidate Genes

Taking the intersection of the expression files of the TCGA-BLCA and GSE13507 cohorts, we finally enrolled 11,255 genes for the subsequent analysis. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were calculated by the “pROC” package to assess the prognostic ability of all included genes and screen the genes included in the analysis with optimal cutoff values (TCGA-BLCA: 0.60; GSE13507: 0.65). Furthermore, to construct an accurate prognostic model, the least absolute shrinkage and selector operation (LASSO) regression analysis was implemented for screening candidate genes by using the “glmnet” package. The minimum lambda value was defined as a cutoff point to minimize the mean cross-validated error. These genes selected via LASSO analysis were used to calculate the risk score of each patient with the gene expression value and coefficient. The process of the current study is shown in Figure 1.

Enrichment Analysis of Selected Genes

The genes with the top mean AUC in both TCGA-BLCA and GSE13507 cohorts were visualized with a heatmap using the R function “heatmap.2” of the “gplots” package. Go and Liang 15-Top-Prognostic-Genes Signature for Bladder Cancer
Overall Survival Analysis and Cox Survival Analysis
Kaplan–Meier (K-M) survival analysis and a log-rank test were performed based on the data of candidate gene expression profiles and corresponding clinical parameters to evaluate survival rates by using the “survival” package. The Cox model was established to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariate Cox regression curves were generated to explore the independent prognostic effect of risk scores after adjusting for several clinical characteristics, including age, sex, and grade. The results were illustrated with multiformet plots. To further explore the impact of the classifier on the prognosis of different subgroups, we conducted a subgroup analysis based on clinical features related to prognosis, including age (≤70 or >70), tumor stage (≤Stage II or >Stage II), sex (male or female), and grade (low or high).

Prediction of the Response to Targeted Therapy
We predicted the chemotherapeutic response for each sample based on the Genomics of Drug Sensitivity in Cancer (GDSC). Six commonly used chemotherapy drugs, cisplatin, doxorubicin, mitomycin, paclitaxel, vinblastine, and gemcitabine, were selected for assessment. We compared the response to the above six drugs via the estimation of the samples’ half-maximal inhibitory concentration (IC50) conducted by ridge regression. To evaluate the individual likelihood of responding to immunotherapy, a subclass analysis was performed in response to anti-PD-L1 therapy based on the clinical response of 248 patients with BCa who underwent immunotherapy (Meng, 2021).

Cell Culture, Proliferation, Invasion, and Western Blotting
We cultured the T24 and 5,637 BCa cell lines in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C with 5% CO2. The BCa cell lines 5,637 and T24 were respectively transfected with 50 pmol negative control, si-HEYL-1#, and si-HEYL-2# inhibitors via Lipofectamine 3,000 (Invitrogen; Thermo Fisher Scientific, Inc.) transfer system. The siRNAs were purchased from Guangzhou Ribobio Co., Ltd., and the sequences are listed in Supplementary Table S1.

We evaluated cell viability via the MTT assay. A total of 5,000 cells were seeded into a 24-well plate and cultured for 0, 1, 2, and 3 days. Then, 50 µl of 0.5% MTT reagent was added to each well, and the cells were further cultured for 1.5 h at 37°C and then detected on a microplate reader. The optical density (OD) values were measured at 450 nm.

For cell invasion, we seeded 20,000 cells in the upper Transwell chamber (8 µm; Corning, Inc.); Matrigel at a 1:20 concentration was precoated and cultured at 37°C for 24 h. The lower chamber
FIGURE 2 | Top prognostic gene selection in both TCGA-BLCA and GSE13507 cohorts. (A) AUC evaluation of the prognostic value of candidate genes involved in overall survival based on datasets TCGA and GSE10816. (B) The average AUC value of the top 11 candidate genes. (C) Annotation of enriched signaling pathways by GO, KEGG, and HALLMARK.
| Terms                                      | p-value | p.adjust | q-value | geneID                                                                 |
|-------------------------------------------|---------|----------|---------|------------------------------------------------------------------------|
| Extracellular matrix organization         | 1.16E-18| 1.26E-15 | 1.06E-15| PLOD1/MMP11/COL16A1/COL18A1/ADAM12/COL5A2/                              |
|                                           |         |          |         | COL5A3/BGN/FAP/COMP/TNC/GREM1/SULF1/                                  |
|                                           |         |          |         | COL5A1/VCAN/LOX/ITGAS/ADAMTS2/COL1A1/COL8A1/AEBP1/ITGA11             |
| Extracellular structure organization      | 1.23E-18| 1.26E-15 | 1.06E-15| PLOD1/MMP11/COL16A1/COL18A1/ADAM12/COL5A2/                          |
|                                           |         |          |         | COL5A3/BGN/FAP/COMP/TNC/GREM1/SULF1/                                |
|                                           |         |          |         | COL5A1/VCAN/LOX/ITGAS/ADAMTS2/COL1A1/COL8A1/AEBP1/ITGA11           |
| Collagen fibril organization              | 6.24E-17| 4.27E-14 | 3.59E-14| PLOD1/MMP11/COL5A2/COL3A1/COL5A3/COMP/GREM1/                          |
|                                           |         |          |         | COL5A1/LOX/ADAMTS2/COL1A1/AEBP1/                                   |
| Ossification                              | 2.40E-09| 1.23E-06 | 1.03E-06| CTHRC1/DCHS1/GL2/COL5A2/COMP/GREM1/VCAN/                              |
|                                           |         |          |         | LOX/COL1A1/RRBP1/ASPIN/TWIST1/ITGA11/FAM20C                        |
| Osteoblast differentiation                | 2.73E-08| 1.12E-05 | 9.41E-06| CTHRC1/GL2/TNC/GREM1/VCAN/LOX/COL1A1/RRBP1/                         |
|                                           |         |          |         | TWIST1/ITGA11/FAM20C                                               |
| ONTOLOGY CC                               |         |          |         |                                                                        |
| collagen-containing extracellular matrix  | 1.63E-15| 3.32E-13 | 2.86E-13| CTHRC1/COL16A1/COL18A1/COL5A2/COMP/                                |
|                                           |         |          |         | COL5A3/BGN/FAP/COMP/TNC/GREM1/                                     |
|                                           |         |          |         | SULF1/COL5A1/VCAN/                                                 |
|                                           |         |          |         | NCAM1/ADAMTS2/CDH2/COL1A1/COL8A1/AEBP1/ASPIN/SERPINE2              |
| collagen trimer                           | 2.52E-11| 2.57E-09 | 2.21E-09| CTHRC1/COL16A1/COL18A1/COL5A2/COMP/                                |
|                                           |         |          |         | COL5A3/COL5A1/LOX/COL1A1/COL8A1/                                   |
| endoplasmic reticulum lumen               | 6.16E-11| 4.19E-09 | 3.61E-09| RCN3/COL16A1/COL18A1/COL5A2/COMP/                                 |
|                                           |         |          |         | COL5A3/COL5A1/VCAN/PDIA5/CDH2/COL1A1/COL8A1/FAM20C/                |
| complex of collagen trimers               | 4.24E-10| 2.16E-08 | 1.86E-08| COL5A2/COL3A1/COL5A3/                                                 |
|                                           |         |          |         | COL1A1/COL8A1/                                                     |
| fibrillar collagen trimer                 | 1.51E-09| 5.14E-08 | 4.43E-08| COL5A2/COL3A1/COL5A3/COL5A1/COL1A1/                                |
| ONTOLOGY MF                               |         |          |         |                                                                        |
| extracellular matrix structural constituent| 1.22E-14| 3.35E-12 | 3.03E-12| CTHRC1/COL16A1/COL18A1/COL5A2/COMP/                                |
|                                           |         |          |         | COL5A3/BGN/FAP/COMP/TNC/GREM1/                                      |
|                                           |         |          |         | SULF1/COL5A1/VCAN/                                                 |
|                                           |         |          |         | NCAM1/ADAMTS2/CDH2/COL1A1/COL8A1/AEBP1/ASPIN/                      |
| extracellular matrix structural constituent conferring tensile strength| 5.00E-11| 6.85E-09 | 6.19E-09| COL16A1/COL18A1/COL5A2/COMP/                                      |
|                                           |         |          |         | COL5A3/COL5A1/VCAN/COL1A1/                                       |
|                                           |         |          |         | COL8A1/AEBP1/ASPN/                                                 |
| glycosaminoglycan binding                 | 4.63E-06| 0.000423 | 0.000382| TNFAP6/COL5A3/BGN/FAP/NRP2/SULF1/                                    |
|                                           |         |          |         | COL5A1/VCAN/                                                      |
|                                           |         |          |         | SERPINE2/                                                      |
| integrin binding                         | 8.05E-06| 0.000552 | 0.000498| COL16A1/COL3A1/FAP/COMP/THY1/                                      |
|                                           |         |          |         | COL5A1/ITGA5/                                                      |
| cell adhesion molecule binding            | 1.79E-05| 0.000983 | 0.000887| PVR/COL16A1/COL3A1/FAP/COMP/THY1/                                  |
|                                           |         |          |         | COL5A1/ITGA5/                                     |
|                                           |         |          |         | CALD1/CDH2/CNN3/FLNA/                                              |
| KEGG                                      |         |          |         |                                                                        |
| Protein digestion and absorption          | 5.22E-07| 7.57E-05 | 6.65E-05| COL16A1/COL18A1/COL1A1/COL3A1/                                      |
|                                           |         |          |         | COL5A1/COL5A2/                                                     |
|                                           |         |          |         | COL5A3/COL8A1/                                                      |
| Glycosphingolipid biosynthesis—ganglio series| 0.000143| 0.010337 | 0.00908 | B4GALNT1/ST3GAL5/ST6GALNAC5                                         |
| ECM–receptor interaction                  | 0.000366| 0.017704 | 0.015551| COL1A1/COMP/ITGA11/ITGA5/TNC/                                      |
| HALLMARK                                  |         |          |         |                                                                        |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION| 2.29E-22| 6.86E-21 | 6.26E-21| ACTA2/ADAM12/BGN/CALD1/CALU/CDH2/COL16A1/                          |
|                                           |         |          |         | COL1A1/COL3A1/COL5A1/COMP/THRC1/FAP/                              |
|                                           |         |          |         | COM/GREM1/ITGA5/LOX/ITGAS/ADAMTS2/PLOD1/PRRX1/PVR/                |
|                                           |         |          |         | SERPINE2/TAGLN/THY1/TNC/VCAN/                                      |
| HALLMARK_MYOGENESIS                       | 7.61E-05| 0.001142 | 0.001041| ACTC1/ADAM12/AEBP1/CNN3/COL1A1/COL3A1/DTNA/                        |
|                                           |         |          |         | MAPK12/NCAM1/SPK1/TAGLN/                                           |
| HALLMARK_ANGIOGENESIS                     | 0.001434| 0.01434  | 0.013082| COL3A1/COL5A2/KCNJ8/VCAN/                                           |
was filled with complete medium as a chemoattractant. After culturing the coculture system at 37°C for 24 h, the chamber and cells were mixed with formalin for 15 min and further stained with 1% crystal violet. The invaded cells were counted in 3 repeated groups (magnification, ×200) under a light microscope (Nikon Corporation).

FIGURE 3 | The network and chord graph shows the most important pathways. (A) Network of enriched signaling pathways; (B) Chord graph of the enriched signaling pathways.
FIGURE 4 | Establishment of the prognostic model (A) Heatmap showing the expression of 107 candidate genes in the TCGA-BLCA cohort. (B) Heatmap showing the expression of 107 candidate genes in the GSE13507 cohort. (C) The optimal tuning parameter (lambda) in the LASSO analysis selected with 5-fold cross-validation and one standard error rule. (D) LASSO coefficient profiles of the 107 candidate genes.
Western blotting was performed to confirm the knockdown of HEYL at the protein level. Anti-HEYL and anti-tubulin antibodies were used to detect the protein lanes.

Statistical Analysis
All analyses were completed by R software v4.0.3 (http://www.r-project.org). The risk score of each BCa patient was calculated with the sum of the selected 15 gene coefficients by LASSO regression. The high-risk group and low-risk group were discriminated by the median value of the risk score. Heatmap and enrichment analyses were applied to the visualized expression files. K-M survival analysis was performed to explore the survival difference between the high-risk and low-risk score groups. A log-rank test was used to estimate the survival analysis. HR and 95% CI were calculated by the Cox model. The independent prognostic effect of the risk score was calculated by multivariate Cox regression analysis. p < 0.05 was considered a statistically significant difference.

RESULT
Gene Selection
In total, 403 patients with 14,163 genes in TCGA-BLCA and 165 patients with 18,561 genes in GSE13507 were first enrolled, and the corresponding clinical information was also downloaded. Following preprocessing of raw data, 11,255 intersecting genes were subjected to the calculation of AUC to estimate the prediction of the prognosis of BCa patients in those two cohorts (Figure 2A). Genes with the top mean AUC are shown in Figure 2B, including “Grem1”, “CLIP3”, “PpibP2”, “Col5a1”, “Cthrc1”, “Olflm2b”, “Col5a3”, “Calu”, “Islr”, “Col1a1”, and “Dnm1”. With the preset cutoff value of AUC (TCGA-BLCA: 0.60; GSE13507: 0.65), we finally enrolled 107 genes for the subsequent analysis.

Intersection Gene Enrichment and Annotation
For the enrolled 107 candidate genes, we performed enrichment analysis to reveal their potential function in BCa. The results demonstrated the top five biological process, cellular component, and molecular function GO terms, KEGG terms, and HALLMARK terms (Figure 2C). We concluded that the extracellular matrix structural process, cell adhesion molecule binding, ECM–receptor interaction, and hallmark epithelial–mesenchymal transition signaling pathways play pivotal roles in the tumorigenesis of BCa. The details of the enriched pathways and genes are displayed in Table 1. The interrelation of the top 30 enriched biological processes is presented in Figure 3A, and the correlation between intersected genes and extracellular matrix-associated signaling is also illustrated in Figure 3B.

Construction of the Prognostic Signature
The gene expression of 107 genes and associated clinical features for the TCGA-BLCA cohort are shown in Figure 4A, and those for the GSE13507 cohort are shown in Figure 4B. LASSO regression was performed to identify candidate genes and evaluate the corresponding coefficients in the TCGA-BLCA training cohort (Figures 4C,D). Based on the minimum lambda value of 0.032, a total of 15 genes were enrolled for the calculation of the prognostic signature, with the formula risk score = 0.109 x expression of PHGDH + 0.117 x expression of CD96 + 0.007 x expression of SETBP1 + 0.077 x expression of GALK1 + 0.019 x expression of DTNA + 0.064 x expression of SERPINB2 + 0.018 x expression of COMP + 0.043 x expression of CALM1 + 0.111 x expression of HEYL + 0.022 x expression of CNCN4L + 0.032 x expression of FADS2 + 0.083 x expression of TMEM109 – 0.013 x expression of CTSE + 0.021 x expression of FAM43A + 0.022 x expression of IL9R. The risk score for each patient in both TCGA-BLCA and GSE13507 cohorts was calculated along with the above-mentioned formula. For the subsequent analysis, the prognostic value of each single gene is displayed in Supplementary Figure S1.

Prognostic Value of the Newly Defined Signature
With the median risk score as the cutoff point, patients in the TCGA-BLCA cohort were divided into the high-risk class (n = 201) and low-risk class (n = 198) (Supplementary Figure S2A), and the results of the risk map showed a significant survival difference between the two classes (Supplementary Figure S2A). K-M curves demonstrated that the low-risk class had a better overall survival time than the high-risk class (p < 0.001, HR = 2.41, 95% CI: 1.76–3.29) (Figure 5A), and the ROC curve showed that the AUC of this classification strategy could be 0.727, with a 95% CI of 0.678–0.776, which indicated an outstanding prognostic value (Figure 5B). The distribution of the clinical features in the high-risk and low-risk groups of TCGA-BLCA are listed in Table 2. We also assessed the prognostic value in different subgroups of patients. The signature was meaningful for BCa patients in the subgroups of age ≤ 70 years old (p < 0.01), age > 70 years old (p < 0.01), Stage I + II (p = 0.02), Stage III + IV (p < 0.01), male sex (p < 0.01), and high grade (p < 0.01) in the TCGA-BLCA cohort (Supplementary Figure S3).

Assessing the Prognostic Value of the Signature in the Testing GSE13507 Cohort
To validate the 15-gene signature predictive values in other BCa cohorts, the same formula was conducted in the GSE13507 dataset to generate the risk score of each patient. Similarly, patients were divided into a high-risk group and a low-risk group based on the median risk score as the cutoff point (Supplementary Figure S2B). Consistent with the results in the TCGA-BLCA cohort, the low-risk group exhibited a shorter overall survival time than the high-risk group (p < 0.001, HR = 7.32, and 95% CI: 1.76–3.29, Figure 5C), and the AUC was 0.786, with a 95% CI of 0.703–0.869 (Figure 5D). The distribution of the clinical features in the high-risk and low-risk groups of GSE13507 is listed in Table 3. We also assessed the
prognostic value in different subgroups of patients. The signature was meaningful for BCa patients in the subgroups of age ≤ 70 years old ($p < 0.01$), age > 70 years old ($p < 0.01$), Stage I + II ($p = 0.027$), male ($p < 0.01$), female ($p < 0.01$), low grade ($p = 0.018$), and high grade ($p < 0.01$) in the GSE13507 cohort (Supplementary Figure S4).
Assessing the Prognostic Value of the Signature in the External Validation E-MTAB-4321 Cohort

To validate the 15-gene signature predictive values in other BCa cohorts, the same formula was conducted in the E-MTAB-4321 dataset to generate the risk score of each patient. Similarly, patients were divided into a high-risk group and a low-risk group based on the median risk score as the cutoff point (Supplementary Figure S2C). Consistent with the results in the TCGA-BLCA cohort, the low-risk group exhibited a shorter overall survival time than the high-risk group (p < 0.001, HR = 10.56, and 95% CI: 3.21–34.73, Figure 5E), and the AUC was 0.829, with a 95% CI of 0.758–0.900 (Figure 5F). We also assessed the prognostic value in different subgroups of patients. The signature was meaningful for BCa patients in the subgroups of age ≤ 70 years old (p = 0.004), age > 70 years old (p < 0.001), stage CIS and Ta (p = 0.004), stage T1–T4 (p = 0.019), male sex (p < 0.001), low grade (p < 0.001), and high grade (p = 0.045) in the E-MTAB-4321 cohort (Supplementary Figure S5). Independent Prognostic Value of the Risk Score

To further explore the signature usage, multivariate Cox regression analysis was performed in the TCGA-BLCA cohort, and as the results showed, age, stage, and risk score were independent prognostic factors (p < 0.001). Even after adjusting for the impact of other clinical features, the signature defined high-risk patients as having an approximately 2.22-fold higher risk of death than low-risk patients (Figure 6A). A combined nomogram enrolling both the signature classifier and other clinical features demonstrated a better prognostic value (AUC: 0.740, 95% CI: 0.683–0.796, Figure 6B). For the GSE13507 cohort, we also revealed similar findings. The prognostic signatures defined as high-risk patients had a 2.90-fold higher risk of death than low-risk patients, which acted as an independent prognostic factor after adjusting for the features of age, tumor stage, sex, and grade (Figure 6C). Moreover, the combined nomogram illustrated a prognostic AUC value as high as 0.960, with a 95% CI of 0.928–0.992 (Figure 6D). For the E-MTAB-4321 cohort, the prognostic signatures defined as high-risk patients had a 6.13-fold risk of BCa recurrence compared with low-risk patients, which acted as an independent prognostic factor after adjusting for the features of age, T stage, sex, and grade (Figure 6E). The combined nomogram illustrated a prognostic AUC value as high as 0.912, with a 95% CI of 0.866–0.959 (Figure 6F).

Exploring the Appropriate Targeted Therapy for BCa Patients

Six chemotherapy drugs, cisplatin, doxorubicin, mitomycin, paclitaxel, vinblastine, and gemcitabine, are commonly used for the clinical treatment of BCa. We compared the response of the six drugs by assessing the IC50 after comparison with the GDSC data. We found that patients in the high-risk group were more suitable for treatment with gemcitabine, doxorubicin, cisplatin, paclitaxel, and vinblastine (all p < 0.05), but not mitomycin (p = 0.06, Figure 7A). For immunotherapy, especially anti-PD-L1 therapy, we employed the gene expression data of the IMvigor210 cohort. After comparing the similarity of the gene expression profile of responders with the patients in both the high-risk and low-risk groups, we found that both patients in the two subgroups were not suitable for treatment with anti-PD-L1 therapy (Figure 7B).

Knockdown of HEYL Inhibited the Proliferation and Invasion of BCa Cells

To evaluate the functions of the newly defined signature, we evaluated the phenotypic alterations of BCa cells after knockdown HEYL, due to the fact that HEYL was given a large weight of 0.111 in the risk score formula. We transfected the control, si-HEYL-1#, and si-HEYL-2# by the Lipofectamine 3,000 system to both T24 and 5,637 cells and observed decreased protein levels of HEYL (Figures 8A,B). Cell viability was also inhibited after knockdown by two siRNAs (Figures 8A,B). For cell invasion, which represents tumor malignancy, we observed similar results: the invaded cell numbers significantly decreased.

| TABLE 2 | Summary of clinical features in the TCGA-BLCA cohort. |
|----------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|          | Level           | Low risk        | High risk       | p               |
| Survival time | 29.43 ± 28.66   | 23.79 ± 25.37   | <0.001          |
| Survival status (%) | 0 | 140 (70.7) | 84 (41.8) | <0.001          |
| Stage (%) | <Stage II | 84 (42.4) | 45 (22.4) | <0.001          |
|          | >Stage II      | 114 (57.6)     | 156 (77.6)     | <0.001          |
| Sex (%) | Female | 44 (22.2) | 61 (30.3) | 0.084           |
|          | Male           | 154 (77.8)     | 140 (69.7)     |                |
| Grade (%) | High | 179 (90.4) | 200 (99.5) | <0.001          |
|          | Low            | 19 (9.6)       | 1 (0.5)        |                |
| Age      | 66.62 ± 10.64  | 69.08 ± 10.24   | 0.019           |
| Signature | 1.92 ± 0.33     | 2.69 ± 0.26     | <0.001          |

| TABLE 3 | Summary of clinical features in the GSE13507 cohort. |
|----------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|          | Level           | Low risk        | High risk       | p               |
| Survival time | 55.60 ± 37.87   | 29.70 ± 30.42   | <0.001          |
| Survival status (%) | 0 | 108 (90.8) | 25 (54.3) | <0.001          |
| Stage (%) | <Stage II | 106 (89.1) | 23 (50.0) | <0.001          |
|          | >Stage II      | 13 (10.9)      | 23 (50.0)      |                |
| Sex (%) | Female | 17 (14.3) | 13 (28.3) | 0.063           |
|          | Male           | 102 (85.7)     | 33 (71.7)      |                |
| Grade (%) | High | 27 (22.7) | 33 (71.7) | <0.001          |
|          | Low            | 92 (77.3)      | 13 (28.3)      |                |
| Age      | 64.59 ± 12.66  | 66.72 ± 9.98   | 0.258           |
| Signature | 4.57 ± 0.26     | 5.26 ± 0.19     | <0.001          |
in the si-HEYL-1# (all \( p < 0.001 \), **Figure 8C**) and si-HEL-2# (all \( p < 0.01 \), **Figure 8D**) groups compared with the control group in both T24 and 5,637 cells.

**DISCUSSION**

BCa ranks as the fourth most common malignant cancer among men in the Western world (Kirkali et al., 2005). BCa is a type of tumor with a strong correlation between age and sex. The median age at diagnosis is approximately 65–70 years old. The incidence rate in men is 3–4 times that in women (Chen et al., 2018). However, according to the Global Cancer Incidence and Mortality Survey, the age-standardized rates (ASRs per 100,000) of women are 5.7, and the ASRs of men are 9.6, suggesting that the stage-adjusted survival of BCa in women is poorer than that in men (Ferlay et al., 2019). There is a detectable difference among variant races and regions or countries. For
instance, white Americans are more susceptible to BCa than African Americans. On the other hand, white Americans are more likely to evolve into invasive tumors and have a higher mortality rate than African Americans (Uno et al., 2000). With the development of sequencing and complementary technologies, molecular classification methods based on genes have been increasingly studied. Compared to the traditional pathology-based classification, a novel subtyping strategy involves more tumor biological information and is expected to have broad application prospects.

Great progress has been made in the study of gene expression profiles and cancer prognosis. For instance, patients with HER2-enriched breast cancer have poor clinical outcomes, but they are sensitive to neoadjuvant chemotherapy, which can greatly benefit this group (Ross et al., 2003). However, only limited data are available for predicting BCa and prognosis to date. Different teams generate a distinct subtyping system, and each has its own characteristics and validity. Either they were created to cater to a specific clinical therapy project or relied on a robust statistical method without considering the cancer biological process at data analysis (Zhu et al., 2020). In our study, we downloaded two data sets from different sources, and a total of 107 prognostic genes were identified for LASSO analysis. To further explore the functions of the 107 candidate genes, GO enrichment analysis was performed. As the results showed, the candidate gene expression was mainly involved in five pathways, including extracellular matrix organization, extracellular structure organization, ossification, collagen fibril organization, and osteoblast differentiation. Moreover, we established the prognostic signature by LASSO analysis of selected genes and

FIGURE 7 | Identification of appropriate targeted therapy for BCa patients. (A) Appropriate chemotherapy for signature-defined high-risk and low-risk patients. (B) Appropriate anti-PD-L1 immunotherapy for signature-defined high-risk and low-risk patients.
generated a risk predictive model with one of them. The formula risk score = \( \sum_{i=1}^{n} \alpha p_i X_i \) (\( \alpha \) represent coef. min) was used to calculate the risk score of each patient. Selecting an optimal cutoff point, the high-risk group and low-risk group were separated. With a robust statistical method, we found that patients in the high-risk group exhibited a worse prognosis than those in the low-risk group. Independently, the same formula and statistical strategy were performed on the testing GSE13507 cohort and external validation E-MTAB-4321 cohort to assess the efficacy of the model, and the result was similar to that in the TCGA-BLCA cohort. Furthermore, we also realized that the newly defined signature is an independent prognostic signature after adjusting for the clinical features of age, tumor stage, sex, and grade.

For the 15 genes enrolled for the calculation of the prognostic signature, several basic experiments have already demonstrated their function in the tumorigenesis of BCa. DNTA plays a role in cell signal transduction and mediates the Notch1 pathway axis. This pathway was reported to be an essential regulator in cell proliferation, differentiation, and apoptosis (Kim M. Y et al., 2010), and the Notch1 pathway has also been proven to contribute to the metastasis of various malignancies, including ovarian, breast, lung, and renal cancer (Kong et al., 2016). HEYL is the target gene of the Notch1 pathway, and there is limited information on the impact of its target gene HEYL. The results of Weber et al. showed that an enhanced expression level of HEYL decreased cancer cell dissemination and the absolute number of metastases formed, while the capacity of cell metastasis remained good, indicating that HEYL can function as a negative regulator by inhibiting the infiltration of metastasis-initiating cells (Weber et al., 2019). At the same time, we found two other tumor suppression genes, SETBP1 and SULF1 (Lai et al., 2008; Li et al., 2020). It was reported that decreased expression of SETBP1 contributed to the development of non-small-cell lung
cancer cells by increasing tumor cell proliferation, migration, and invasion and was associated with poor prognosis. In addition, other studies have claimed that SETBP1 expression is associated with acute myeloid leukemia and that microRNA-211-5p directly targets SETBP1 to inhibit triple-negative breast cancer cell proliferation, migration and metastasis (Chen et al., 2017). SULF1 is increasingly considered for its tumor suppressor effect. The target pathways related to the effect of SULF1 include hedgehog, Wnt, and multiple heparan sulfate-dependent receptor tyrosine kinase pathways, which may prove to be an important method to prevent and treat cancer (Lai et al., 2008).

We also revealed six oncogenes that have been validated to be related to the poor prognosis of patients with cancer: CTSE, CALM1, PHGDH, IL9R, and CD96 (Boulay et al., 2001; Possemato et al., 2011; Yan et al., 2011; Pontious et al., 2019; Salazar et al., 2020; Zhao et al., 2020; Liu et al., 2021). CTSE is an intracellular hydrolytic aspartic protease that has been found to be overexpressed in cancer tissues. With the help of endoscopy and immunosorbent assay (ELISA) and Western blot, CTSE was considered a better biomarker than CA19-9 for detecting pancreatic cancer. CALM1, a calcium ion (Ca2+) receptor protein, is responsible for mediating various signaling processes. Overexpression of CALM1 in cancer is significantly related to clinical stage, T classification, and poor prognosis. The function of CALM1 depends on the synergy of ERGF, and similar to anti-EGFR antibodies, CALM1 inhibitors play an essential role in cancer chemotherapy (Liu et al., 2021). PHGDH is a key enzyme in the serine synthesis pathway. Serine is an intermediate of other amino acids and lipid and nucleic acid synthesis pathways (Locasale et al., 2011) and thus promotes cancer progression. Studies have shown that PHGDH is a reliable biomarker and independent factor predicting prognosis (Song et al., 2018). IL9 is a multifunctional cytokine involved in many pathways in the cell and plays opposite roles in different tumors. For instance, IL9 inhibited the proliferation of the gastric cancer cell line SGC-7901 in vitro (Cai et al., 2019) through the activation of adaptive or innate immune responses. However, IL9 can act as a tumorigenic factor or an enhancing factor to promote the proliferation of hematological tumors and some solid tumors (Chen and Wang, 2014; Hu et al., 2017). CD96 is mainly involved in immune function, especially the immune response mediated by T cells. CD96 can promote cancer metastasis by enhancing NK cell-target adhesion and inhibiting the NK-mediated cytokine response (Liu et al., 2020). Interestingly, high expression of CD96 inhibits IL9 production in Th9 cells (Stanko et al., 2018).

The expression level of SERPINB2 was consistent with carcinogen exposure, indicating that SERPINB2 may provide sensitive and accurate information for the beginning of tumorigenic events (Lee et al., 2019). SERPINB2 was also reported as a regulator or biomarker for predicting the malignant progression of colorectal and bladder cancer (Ganesh et al., 1994; Champelovier et al., 2002). Importantly, an increase in SERPINB2 was detected with most of the additional tested tumorigenic substances, which adds more evidence for SERPINB2 as a potential biomarker. Liu et al. found that COMP was an excellent prognostic factor and biomarker of colon cancer equivalent to noninvasive biomarker performance, such as CA-199 (Liu et al., 2018). Studies have shown that COMP contributes to the development and metastasis of breast cancer. The enhanced expression level of COMP in tumor cells is significantly related to the reduced breast cancer-specific survival rate and recurrence-free survival rate of patients, while the expression level of COMP in the stroma has a poor connection with prognosis (Englund et al., 2016). CCRN4L, a type of clock-control gene, is a key component in the regulation of circadian rhythms (Filipski and Levi, 2009). It was considered that the expression of clock-control genes changed in some cancer groups, and polymorphisms in the CCRN4L gene may contribute to the genesis of NSCLC in Brazilian patients (Couto et al., 2014). FADS2 is a potential oncogene (Tian et al., 2020). Several cancers have been validated to utilize FADS2 to desaturate palmitate to the unusual fatty acid sapienate, which can be applied to the biosynthesis of the membrane. Sapienate biosynthesis is an alternative method for fatty acid desaturation metabolism in cancer cells (Vriens et al., 2019).

As we know, this is the first study that concerned the top prognosis prediction genes to construct the signature; we selected the top prognostic genes with the high AUC values in both TCGA-BLCA and GSE13507 cohorts, and the highly prognostic efficacy of the 15-gene signature was displayed in both TCGA-BLCA and GSE13507 cohorts, as well as the external validation E-MTAB-4321 cohort. Meanwhile, several limitations of the current study should be illustrated. First, real-world patient cohort is needed to further validate the prognostic value of the 15-gene signature. Second, experimental studies of the enrolled 15 genes are necessary to further reveal the potential mechanisms of them in BCa tumorigenesis. Third, the strength of evidence for the significance of therapy is not enough, and further mechanism study and clinical experiment should be conducted to evaluate the targeted therapy efficacy.

**CONCLUSION**

As gene mutation events accumulate, tumor cells gradually develop. Molecular changes occur earlier than clinical symptom onset and overt radiographic evidence. Therefore, molecular classifiers are considered promising tools for the early prediction of tumors. BCa is a disease with multiple factors and heterogeneity, and traditional classification cannot reflect the actual situation and prognosis. In the current study, we enrolled 15 genes that can delineate BCa from multiple angles, and the 15-gene classifier was validated to be associated with the clinical outcome and response to targeted therapy of patients with BCa.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
AUTHOR CONTRIBUTIONS

HG designed the study, and CL analyzed the data, wrote the figures, and drafted the manuscript; GL revised the whole paper and approved the final paper. All authors read and approved the final manuscript.

REFERENCES

Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., et al. (2017). Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 71 (1), 96–108. doi:10.1016/j.eururo.2016.06.010

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fcell.2022.725024/full#supplementary-material
Possemato, R., Marks, K. M., Shaull, Y. D., Pacold, M. E., Kim, D., Birsoy, K., et al. (2011). Functional Genomics Reveal that the Serine Synthesis Pathway Is Essential in Breast Cancer. *Nature* 476 (7360), 346–350. doi:10.1038/nature10350

Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., et al. (2003). The Her-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. *Oncologist* 8 (4), 307–325. doi:10.1634/theoncologist.8-4-307

Salazar, Y., Zheng, X., Brunn, D., Raifer, H., Picard, F., Zhang, Y., et al. (2020). Microenvironmental Th9 and Th17 Lymphocytes Induce Metastatic Spreading in Lung Cancer. *J. Clin. Invest.* 130 (7), 3560–3575. doi:10.1172/JCI124037

Sjödahl, G., Lauss, M., Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., et al. (2012). A Molecular Taxonomy for Urothelial Carcinoma. *Clin. Cancer Res.* 18 (12), 3377–3386. doi:10.1158/1078-0432.Ccr-12-0077-t

Song, Z., Feng, C., Lu, Y., Lin, Y., and Dong, C. (2018). PHGDH Is an Independent Prognosis Marker and Contributes Cell Proliferation, Migration and Invasion in Human Pancreatic Cancer. *Gene* 642, 43–50. doi:10.1016/j.gene.2017.11.014

Stanko, K., Iwert, C., Appelt, C., Vogt, K., Schumann, J., Strunk, F. J., et al. (2018). CD96 Expression Determines the Inflammatory Potential of IL-9-producing Th9 Cells. *Proc. Natl. Acad. Sci. USA* 115 (13), E2940–e2949. doi:10.1073/pnas.1708329115

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene Set Enrichment Analysis: a Knowledge-Based Approach for Interpreting Genome-wide Expression Profiles. *Proc. Natl. Acad. Sci. USA* 102 (43), 15545–15550. doi:10.1073/pnas.0506580102

Tian, J., Lou, J., Cai, Y., Rao, M., Lu, Z., Zhu, Y., et al. (2020). Risk SNP-Mediated Enhancer–Promoter Interaction Drives Colorectal Cancer through Both FADS2 and AP002754.2. *Cancer Res.* 80 (9), 1804–1818. doi:10.1158/0008-5472.CAN-19-2389

Tsang, J. Y. S., and Tse, G. M. (2020). Molecular Classification of Breast Cancer. *Adv. Anat. Pathol.* 27 (1), 27–35. doi:10.1097/pap.0000000000002322

Uno, K., Azuma, T., Nakajima, M., Yasuda, K., Hayakumo, T., Mukai, H., et al. (2000). Clinical Significance of Cathepsin E in Pancreatic Juice in the Diagnosis of Pancreatic Ductal Adenocarcinoma. *J. Gastroenterol. Hepatol.* 15 (11), 1333–1338. doi:10.1046/j.1440-1746.2000.02351.x

Vriens, K., Christen, S., Parik, S., Broekaert, D., Yoshinaga, K., Talebi, A., et al. (2019). Evidence for an Alternative Fatty Acid Desaturation Pathway Increasing Cancer Plasticity. *Nature* 566 (7744), 403–406. doi:10.1038/s41586-019-0904-1

Weber, S., Koschade, S. E., Hoffmann, C. M., Dubash, T. D., Giessler, K. M., Dieter, S. M., et al. (2019). The Notch Target Gene HEYL Modulates Metastasis Forming Capacity of Colorectal Cancer Patient-Derived Spheroid Cells. *In Vivo. BMC Cancer* 19 (1), 1181. doi:10.1186/s12885-019-6396-4

Yan, D., Dai, H., and Liu, J.-W. (2011). Serum Levels of MMP-11 Correlate with Clinical Outcome in Chinese Patients with Advanced Gastric Adenocarcinoma. *BMC Cancer* 11, 151. doi:10.1186/1471-2407-11-151

Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. *OMICS: A J. Integr. Biol.* 16 (5), 284–287. doi:10.1089/omi.2011.0118

Zhan, X., Fu, J., Du, J., and Xu, W. (2020). The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer. *Int. J. Biol. Sci.* 16 (9), 1495–1506. doi:10.7150/ijbs.41051

Zhu, S., Yu, W., Yang, X., Wu, C., and Cheng, F. (2020). Traditional Classification and Novel Subtyping Systems for Bladder Cancer. *Front. Oncol.* 10, 102. doi:10.3389/fonc.2020.00102

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gu and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.